Biotech Startups

1 investor

Austrianova is a biotech company that manufactures cell-based products using encapsulation technology and GMP-grade processes. The company serves pharmaceutical and biotech firms developing cell therapies, with quality systems and data infrastructure based in Germany and Switzerland.

1 investor

AustroCel Hallein is a biorefinery company that processes wood into biochemical and bioenergy products with a focus on sustainability. The company operates as one of Europe's leading integrated biorefineries, leveraging wood resources across the full value chain.

1 investor

AutoGenomics develops genetic testing platforms for clinical reference labs, specialty clinics, and hospital laboratories. The company's microarray technology enables multiplexed genetic marker detection and analysis for personalized medicine diagnostics.

1 investor

AutoIVF builds chip-based microfluidic systems that automate embryology steps in IVF laboratories, including its OvaReady product for oocyte preparation using a software-controlled instrument and single-use microfluidic kit. It targets IVF clinics and fertility labs, aiming to reduce operator variability and standardize laboratory workflows.

1 investor

Automera develops an autophagy-powered small molecule degrader platform designed to accelerate drug development and reduce costs in therapeutic creation. The company targets pharmaceutical and biotech organizations seeking novel technologies for small molecule drug discovery.

1 investor

Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.

1 investor

AuX Labs uses precision fermentation to produce casein and other milk proteins without animals, giving microorganisms the genetic blueprint to make dairy proteins. It targets food manufacturers, CPG brands, and food-service operators seeking animal-free dairy ingredients that match conventional dairy's taste and functionality.

1 investor

Aeris Biosciences (formerly Auxilium Health) develops biomaterials for regenerative medicine. The company is composed of scientists, engineers, and clinicians working in the human health field.

1 investor

Auxilius Pharma develops value-added cardiovascular medications by reformulating existing drugs into optimized dosage forms to improve patient outcomes. The company serves patients, healthcare providers, and payors by addressing unmet needs in cardiovascular health through enhanced drug delivery.

1 investor

Avana Health is a women's health company developing uterine health treatments for abnormal uterine bleeding (AUB) and postpartum hemorrhage (PPH), and is preparing for its first clinical trials. Its treatments target unmet needs in maternal and gynecological care and are intended to be affordable and accessible to providers globally.

1 investor

Avania is a clinical development and regulatory consulting firm that supports medical device companies through product development, clinical trial execution, and FDA regulatory submissions. The company serves medtech innovators navigating complex regulatory pathways from early-stage concept to market clearance.

1 investor

Avant Genomics is developing an automated platform for liquid biopsy sample preparation, using an enclosed fluidic cartridge and benchtop instruments that integrate DNA enrichment and purification for blood-based cancer detection. The system targets research labs, clinical testing environments, and reference laboratories aiming to reduce manual labor and cost in precision oncology workflows.

1 investor

AvantGuard, a Cornell University spin-out originally founded as Halomine, develops N-halamine-based antimicrobial and surface-protection technology aimed at combating pathogens including the fungus Candida (Candidozyma) auris. The company is advancing an antifungal decolonization protocol toward FDA approval, targeting fungal skin and nail infections and healthcare antiseptic applications.

1 investor

VWR (part of Avantor) is a distributor of laboratory and production products and services, offering life science reagents, chemicals, lab equipment, consumables, safety/PPE, and furniture. It also provides procurement, supply chain, equipment servicing, and digital commerce/inventory software for research, biopharma, healthcare, and industrial customers.

1 investor

Aventera Antibodies is a preclinical biotech developing a first-in-class precision immunotherapy — an engineered monoclonal antibody — against invasive Group A Streptococcal (iGAS) infections, with first-in-human trials planned for 2028. The therapy is intended to be paired with rapid Strep-A diagnostics to enable early clinical intervention.

1 investor

Aventi is a clinical-stage biopharmaceutical company developing therapeutics for sarcopenia, with plans to treat geriatric sarcopenia and expand to other age-related diseases. It operates in the biotechnology and pharmaceutical industry.

1 investor

Avenue Biosciences develops machine learning-enabled chemistry and software to accelerate the discovery and manufacturing of protein biologics for the biotechnology and therapeutics industry. The company combines high-throughput chemistry with computational tools to overcome production barriers in protein drug development.

1 investor

AVEO, operating as a subsidiary of LG Chem, develops and commercializes oncology medicines aimed at cancer patients seeking effective treatments that maintain quality of life. The company operates a portfolio of on-market and in-development therapeutic products globally.

1 investor

Averywell develops a non-invasive, miRNA-based liquid blood test for early lung cancer detection and lung nodule management, using AI and machine learning to analyze microRNA profiles. The test targets both smokers and non-smokers as an at-risk screening population.

1 investor

Avesta Bio is a biotech company developing cancer therapeutics by targeting oxidative stress and its role in disease, based on the approach of identifying what is common across cancer cells rather than what differs. Its research points to methods of killing many cancer cell types without harming normal cells, with potential applications to other metabolic diseases.

1 investor

Avid Bio provides development and manufacturing services for biologics programs, offering integrated support from early-stage development through commercialization. The company partners with pharmaceutical and biotech teams as a contract development and manufacturing organization (CDMO) with US-based operations.

1 investor

Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.

1 investor

Zimmer Biomet's Avitus Bone & Marrow Harvester is a minimally invasive suction curettage device designed for orthopedic surgeons to harvest cancellous bone and bone marrow, and to debride infected or diseased bone through small incisions at accessible sites like the tibia and calcaneus. The sterile-packed, disposable system enables percutaneous autologous bone and marrow harvesting for surgical grafting procedures.

1 investor